Storia in 4 fonti

Teplizumab Approval Expands to Early Type 1 Diabetes

Product aims to disrupt the autoimmune attack against insulin-producing beta cells

Raccontata da

Confronto fonti

4 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo16 h fa

Teplizumab Approval Expands to Early Type 1 Diabetes

Product aims to disrupt the autoimmune attack against insulin-producing beta cells

originale

healio.com1 g fa

FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes

Sanofi's Tzield received FDA approval for pediatric type 1 diabetes stage 3, reducing C-peptide decline to 0.13 pmol/mL vs placebo in a 328-patient trial. The therapy advances autoimmune diabetes treatment, expanding disease-modifying options for children and adolescents.

Leggi questa versione → originale

Timeline cronologica

sabato 13 giugno 2026·morningstar.com
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US
lunedì 15 giugno 2026·healio.com
FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes
The FDA has granted accelerated approval for teplizumab-mzwv as the first disease-modifying therapy for children and adolescents with stage 3 type 1 diabetes, according to an…

Teplizumab Approval Expands to Early Type 1 Diabetes

Confronto fonti

Teplizumab Approval Expands to Early Type 1 Diabetes

FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes

Timeline cronologica

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

FDA approves Tzield to treat children and adolescents with stage 3 type 1 diabetes

Breakthrough T1D Celebrates Approval of Tzield for use in Stage 3 Type 1 Diabetes in the US

FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sanofi (NASDAQ:SNY)

Teplizumab Approval Expands to Early Type 1 Diabetes

FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sanofi (NASDAQ:SNY)